Search research articles
Contact Us
Filters
Showing results (41-50 of 117) with videos related to
Page
of 12
Sort By:
Experimental Neurology
|
April 1, 1997
Spinal cord compression injury in guinea pigs: structural changes of endothelium and its perivascular cell associations after blood-brain barrier breakdown and repair
C B Jaeger, A R Blight
Current Opinion in Investigational Drugs (London, England : 2000)
|
September 27, 2001
Acute spinal cord injury: pharmacotherapy and drug development perspectives
A R Blight, M P Zimber
Experimental Brain Research
|
January 1, 1982
Resetting fast phases of head and eye and their linkage in the frog
N Dieringer, W Precht, A R Blight
Archives of Drug Information
|
November 17, 2009
Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells
Muthukrishnan Renganathan, Serguei Sidach, Andrew R Blight
Experimental Neurology
|
January 24, 1998
Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine
R Shi, T M Kelly, A R Blight
Brain Research
|
December 31, 1993
Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury
A R Blight, K Saito, M P Heyes
Annals of the New York Academy of Sciences
|
August 27, 2014
Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis
Andrew R Blight, Herbert R Henney, Ron Cohen
Journal of Neurotrauma
|
October 8, 1999
Functional reconnection of severed mammalian spinal cord axons with polyethylene glycol
R Shi, R B Borgens, A R Blight
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 8, 2011
Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers
Herbert R Henney, Bonnie Faust, Andrew R Blight
Clinical Therapeutics
|
November 20, 2009
Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study
Timothy Vollmer, Andrew R Blight, Herbert R Henney
Page
of 12
Search research articles
Search
Showing results (41-50 of 117) with videos related to
Sort By:
Page
of 12
Experimental Neurology
|
April 1, 1997
Spinal cord compression injury in guinea pigs: structural changes of endothelium and its perivascular cell associations after blood-brain barrier breakdown and repair
C B Jaeger, A R Blight
Current Opinion in Investigational Drugs (London, England : 2000)
|
September 27, 2001
Acute spinal cord injury: pharmacotherapy and drug development perspectives
A R Blight, M P Zimber
Experimental Brain Research
|
January 1, 1982
Resetting fast phases of head and eye and their linkage in the frog
N Dieringer, W Precht, A R Blight
Archives of Drug Information
|
November 17, 2009
Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells
Muthukrishnan Renganathan, Serguei Sidach, Andrew R Blight
Experimental Neurology
|
January 24, 1998
Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine
R Shi, T M Kelly, A R Blight
Brain Research
|
December 31, 1993
Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury
A R Blight, K Saito, M P Heyes
Annals of the New York Academy of Sciences
|
August 27, 2014
Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis
Andrew R Blight, Herbert R Henney, Ron Cohen
Journal of Neurotrauma
|
October 8, 1999
Functional reconnection of severed mammalian spinal cord axons with polyethylene glycol
R Shi, R B Borgens, A R Blight
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 8, 2011
Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers
Herbert R Henney, Bonnie Faust, Andrew R Blight
Clinical Therapeutics
|
November 20, 2009
Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study
Timothy Vollmer, Andrew R Blight, Herbert R Henney
Page
of 12